Search Results - "STANGIER, J."

A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial by ERIKSSON, B. I., DAHL, O. E., BÜLLER, H. R., HETTIARACHCHI, R., ROSENCHER, N., BRAVO, M‐L., AHNFELT, L., PIOVELLA, F., STANGIER, J., KÄLEBO, P., REILLY, P.

“…Background: Dabigatran etexilate is an oral direct thrombin inhibitor undergoing evaluation for the prevention of venous thromboembolism (VTE) following…”
Get full text

Pharmacokinetic Profile of the Oral Direct Thrombin Inhibitor Dabigatran Etexilate in Healthy Volunteers and Patients Undergoing Total Hip Replacement by Stangier, Joachim, Eriksson, Bengt I., Dahl, Ola E., Ahnfelt, Lennart, Nehmiz, Gerhard, Stähle, Hildegard, Rathgen, Karin, Svärd, Robbyna

“…Dabigatran etexilate is an oral low‐molecular‐weight direct thrombin inhibitor. Following oral administration, dabigatran etexilate is rapidly converted to its…”
Get full text

Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I by Eriksson, B. I., Dahl, O. E., Ahnfelt, L., Kälebo, P., Stangier, J., Nehmiz, G., Hermansson, K., Kohlbrenner, V.

“…Background: Dabigatran etexilate (BIBR 1048) is an oral direct thrombin inhibitor undergoing evaluation for the prevention of venous thromboembolism (VTE)…”
Get full text

AT1 receptor antagonist telmisartan administered peripherally inhibits central responses to angiotensin II in conscious rats by Gohlke, P, Weiss, S, Jansen, A, Wienen, W, Stangier, J, Rascher, W, Culman, J, Unger, T

“…The effects of systemic treatment with the AT1 receptor antagonist telmisartan on central effects of angiotensin II (Ang II), namely, increase in blood…”
Get more information

Pharmacokinetics of Orally and Intravenously Administered Telmisartan in Healthy Young and Elderly Volunteers and in Hypertensive Patients by Stangier, J, Su, CAPF, Roth, W

“…A series of studies was conducted in healthy young males and healthy elderly males or females to evaluate the pharmacokinetic profile of telmisartan. In…”
Get full text

Effect of linagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers by Graefe-Mody, E U, Brand, T, Ring, A, Withopf, B, Stangier, J, Iovino, M, Woerle, H-J

“…To investigate the effect of the estimated highest therapeutic dose of linagliptin (5 mg) on the pharmacokinetics and pharmacodynamics of warfarin, a CYP2C9…”
Get full text

Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity by van Ryn, Joanne, Stangier, Joachim, Haertter, Sebastian, Liesenfeld, Karl-Heinz, Wienen, Wolfgang, Feuring, Martin, Clemens, Andreas

“…Dabigatran etexilate is an oral, reversible direct thrombin inhibitor that is approved in the EU and several other countries for the prevention of venous…”
Get more information

Unusual Cardioactive Peptide (CCAP) from Pericardial Organs of the Shore Crab Carcinus maenas by Stangier, J., Hilbich, C., Beyreuther, K., Keller, R.

“…An unusual crustacean cardioactive peptide (CCAP) from the pericardial organs of the shore crab Carcinus maenas has been purified to homogeneity by a two-step…”
Get full text

Pharmacokinetics of Repeated Oral Doses of Amlodipine and Amlodipine plus Telmisartan in Healthy Volunteers by Stangier, Joachim, Su, Chung-An P. F.

“…This open‐label, crossover study was performed to establish if there is evidence for interaction between telmisartan, an angiotensin II antagonist, and…”
Get full text

Dabigatran With or Without Concomitant Aspirin Compared With Warfarin Alone in Patients With Nonvalvular Atrial Fibrillation (PETRO Study) by Ezekowitz, Michael D., MD, PhD, Reilly, Paul A., PhD, Nehmiz, Gerhard, PhD, Simmers, Timothy A., MD, Nagarakanti, Rangadham, MD, Parcham-Azad, Kambiz, MD, Pedersen, K. Erik, MD, Lionetti, Dominick A., MA, Stangier, Joachim, PhD, Wallentin, Lars, MD, PhD

“…This is the first evaluation of dabigatran, an oral direct thrombin inhibitor, in patients with atrial fibrillation (AF). Patients (n = 502) were randomized to…”
Get full text

Occurrence of crustacean cardioactive peptide (CCAP) in the nervous system of an insect, Locusta migratoria by STANGIER, J, HILBICH, C, KELLER, R

“…Using a radioimmunoassay developed for the determination of crustacean cardioactive peptide (CCAP), immunoreactive material was detected in extracts of locust…”
Get full text

Pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects after oral administration of dabigatran etexilate by Härtter, Sebastian, Yamamura, Norio, Stangier, Joachim, Reilly, Paul A, Clemens, Andreas

“…Ethnic differences in drug disposition may potentially influence therapeutic response to dabigatran, a reversible direct thrombin inhibitor used for the…”
Get more information

An open-label study of the pharmacokinetics and pharmacodynamics of dabigatran etexilate 150 mg once daily in Caucasian patients with moderate renal impairment undergoing primary unilateral elective total knee or hip replacement surgery by Eriksson, Bengt I, Mikuska, Zsolt, Feuring, Martin, Amiral, Jean, Haertter, Sebastian, Stangier, Joachim, Nehmiz, Gerhard, Weitz, Jeffrey I

“…Abstract Background In adults with moderate renal impairment (creatinine clearance [CrCl] 30–50 mL/min) undergoing total hip or knee replacement (THR/TKR), the…”
Get full text

Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis by Liesenfeld, Karl‐Heinz, Schäfer, Hans G., Trocóniz, Iñaki F., Tillmann, Christiane, Eriksson, Bengt I., Stangier, Joachim

“…Aims To describe the pharmacokinetic–pharmacodynamic (PK–PD) characteristics of the direct thrombin inhibitor dabigatran in hip replacement patients by…”
Get full text

Differentialdiagnosen einer unklaren zystischen Raumforderung der Zunge by Baum, S. H., Stangier, J., Heikaus, S., Mohr, C.

Get full text

Differentialdiagnosen einer unklaren zystischen Raumforderung der Zunge by Baum, S. H., Stangier, J., Heikaus, S., Mohr, C.

Get full text

Testosterone-induced diminution of two peptides in spleen cells from testosterone-immunosuppressed B10 mice by Fiebig, S, Schmitt-Wrede, H P, Wunderlich, F, Stangier, J, Schiltz, E

“…High-performance liquid chromatography (HPLC) is used to detect testosterone (T)-sensitive peptides in spleen cells isolated from female C57BL/10 mice…”
Get more information

In vitro and in vivo characterization of the activity of telmisartan: an insurmountable angiotensin II receptor antagonist by Maillard, Marc P, Perregaux, Christine, Centeno, Catherine, Stangier, Joachim, Wienen, Wolfgang, Brunner, Hans-R, Burnier, Michel

“…In vitro studies have shown that telmisartan is an insurmountable angiotensin II subtype-1 (AT1) receptor antagonist. Herein, the molecular basis of this…”
Get more information

Absorption, Metabolism, and Excretion of Intravenously and Orally Administered [14C]Telmisartan in Healthy Volunteers by Stangier, Joachim, Schmid, Jochen, Türck, Dietrich, Switek, Heinz, Verhagen, Aalt, Peeters, Pierre A. M., van Marle, Sjoerd P., Tamminga, Wim J., Sollie, Frans A. E., Jonkman, Jan H. G.

“…The study was conducted in healthy male volunteers to evaluate the absorption, metabolic pattern, and mode of elimination of telmisartan, a nonpeptide…”
Get full text

Pharmacokinetics and Safety of Intravenous and Oral Telmisartan 20 mg and 120 mg in Subjects with Hepatic Impairment Compared with Healthy Volunteers by Stangier, Joachim, Su, Chung-An P. F., Schöndorfer, G., Roth, Willy

“…The pharmacokinetics and safety of telmisartan were assessed in subjects with hepatic impairment in a single‐center, open‐label study. Single oral doses of…”
Get full text